Efficacy and safety of bevacizumab combined with chemotherapy in symptomatic brain metastases from lung adenocarcinoma: a retrospective analysis | Zendy

Qiong Zhan | Zendy; Feng Miao | Zendy; Ruofan Huang | Zendy; Xinli Zhou | Zendy; Mengxi Ge | Zendy; Xiaohua Liang | Zendy

Open Access

Efficacy and safety of bevacizumab combined with chemotherapy in symptomatic brain metastases from lung adenocarcinoma: a retrospective analysis

Author(s) -

Qiong Zhan,

Feng Miao,

Ruofan Huang,

Xinli Zhou,

Mengxi Ge,

Xiaohua Liang

Publication year - 2019

Publication title -

journal of thoracic disease

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.682

H-Index - 60

eISSN - 2077-6624

pISSN - 2072-1439

DOI - 10.21037/jtd.2019.10.49

Subject(s) - medicine , bevacizumab , adenocarcinoma , chemotherapy , hazard ratio , dexamethasone , lung cancer , lung , surgery , oncology , cancer , confidence interval

Currently, the treatment of symptomatic brain metastases from lung adenocarcinoma has remained difficult. Bevacizumab combined with chemotherapy is one of the standard treatments of lung adenocarcinoma. This study was designed to investigate the efficacy and safety of bevacizumab combined with chemotherapy in symptomatic brain metastases from lung adenocarcinoma that are not suitable for local treatments, and to explore the predictive value of baseline serum vascular endothelial growth factor (VEGF) for the treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research